Insiders who reported open-market trades in the last 12 months at the companies Barry D. Quart files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Sanj K. Patel - $39.43M in KNSA purchases and sales in the last 12 months
John F. Paolini - $8.00M in KNSA purchases and sales in the last 12 months
Mark Ragosa - $3.78M in KNSA purchases and sales in the last 12 months
Michael R. Megna - $2.64M in KNSA purchases and sales in the last 12 months
Eben Tessari - $523K in KNSA purchases and sales in the last 12 months
G. Bradley Cole - $299K in KNSA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Barry D. Quart is a corporate insider, tracked as Director of Kiniksa Pharmaceuticals International, plc (KNSA). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Barry D. Quart submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Barry D. Quart been buying or selling stock?
Recorded transactions: 0 open-market purchases and 7 open-market sales ($1.85M) across all tracked filings.
Barry D. Quart is Director of Kiniksa Pharmaceuticals International, plc (KNSA). 6 SEC Form 4 filings on record, most recently on 21 August 2026. Most recent open-market trade: sold $656K of KNSA on 29 April 2026. Lifetime open-market sales: $1.85M.
Recent transactions
16
The latest 16 SEC Form 4 transactions reported by Barry D. Quart.
InsiderAlpha's records for Barry D. Quart go back to 2026: 6 primary Form 4 filings, an average of 6.0 per year. 21 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
